Biotech Values

[apljack]

TTPH"From the lack of response to your query, it sounds like the answer is no. Perhaps you could tell us more about why you like them."

Don't like the per se, but they showed up on my radar as I was doing some looking around. Given the evolution of drug resistant bacteria that have changed the game in health care, I am on the lookout for innovators in this space. That TTPH has a connection with Harvard Med School's office of technology development, appears to be well funded, and may have a technology platform that will allow the development of novel tetracycline and associated antibiotics all have piqued my interest. Read from the Harvard Office Of Technology's announcement regarding the partnership:

"TetraPhase's drug discovery and development efforts are based on fundamental technology developed by Professor Andrew Myers, Ph.D. and his colleagues in the Department of Chemistry and Chemical Biology at Harvard University. The Myers technology overcomes a key barrier to developing new tetracyclines by enabling for the first time their total synthesis from basic building blocks. Dr. Myers and his colleagues published the core synthesis technology in Science in April 2005.

Lawrence Miller, MD, Chairman of the Board, TetraPhase Pharmaceuticals and Partner at Mediphase Venture Partners, stated, "The emergence of drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, is rapidly becoming a major public health challenge. There are few new drugs in development, particularly for community-based infections. With the Myers technology, associated Harvard patents and an experienced, core management team in place, TetraPhase is well positioned to develop a range of novel compounds based on this well-established class of antibiotics. Funding by this strong investor group is a significant endorsement of our approach."

Isaac T. Kohlberg, Senior Associate Provost and Chief Technology Development Officer, Harvard University, stated, "We believe that the ideal development pathway to the clinic for this technology is via a well-funded, professionally managed start-up company fully committed to its advancement. We are pleased that this investment group shares our confidence in the potential of TetraPhase and the Myers technology."

"This financing is the result of a strong and successful relationship with the Harvard Office of Technology Development and our joint commitment to build the framework for a sustainable company," continued Dr. Miller. "TetraPhase acquired the exclusive license to the Myers technology after collaboratively working with the OTD on a comprehensive technology development, finance and commercialization plan."

Tetracyclines are among the most commonly used classes of antibiotics and have proven safe and effective in more than 50 years of clinical use. Previously, all tetracyclines have been "semi-synthetic", that is, primarily synthesized by bacteria, purified, and modified for clinical use. However, the nature of this process markedly limits potential modifications, so that a narrow range of tetracyclines has been synthesized. As a result, only one new tetracycline has been approved in the past 30 years.

"After nearly 10 years of intensive research, my colleagues and I were able to make tetracyclines such as doxycycline, as well as tetracycline itself, from the simple starting material benzoic acid," said Dr. Myers. "We have begun to use this process to make new tetracyclines that were previously inaccessible by any means. Our discovery program has already yielded many novel tetracyclines, which in testing have demonstrated activity against a broad range of bacterial strains, including many resistant to traditional tetracycline antibiotics."

TetraPhase's senior management includes Louis Plamondon, Ph.D., Senior Vice President and Chief Scientific Officer, formerly of Millennium Pharmaceuticals; David Lubner, Senior Vice President and Chief Operating Officer, formerly of IMS Health/PharMetrics and ProScript; and Xiao-Yi Xiao, Ph.D., Vice President of Medicinal Chemistry, formerly of Miikana Therapeutics/Entremed. TetraPhase will be based in Watertown, MA."

http://www.techtransfer.harvard.edu/mediacenter/pr/release/20061124-01.php

This co. might be a one-trick pony (for now; their other candidates are in phase one research), and while the initial indications for Eravacycline may be limited, the need for a new generation of antibiotics is huge.

JM2C

AJ